Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants BTD to Seattle Genetics' brentuximab vedotin

Nov. 11, 2016

FDA approves Opdivo for head and neck cancer

Nov. 11, 2016

FDA removes partial clinical hold on NY-ESO SPEAR study

Nov. 11, 2016

Bristol-Myers Squibb and Infinity Pharmaceuticals sign collaboration

Nov. 10, 2016

Imugene initiates phase Ib/II study of HER-Vaxx in gastric cancer

Nov. 10, 2016

Cell Medica and Baylor to develop off-the-shelf allogeneic cell therapy for cancer

Nov. 10, 2016

5T4 oncofetal antigen as a promising target for immune intervention in cancer

Nov. 9, 2016

DNAtrix in license agreement with University of Florida to develop novel oncolytic virus platform

Nov. 9, 2016

Mylan submits BLA to FDA for proposed trastuzumab biosimilar

Nov. 9, 2016

FDA puts full clinical hold on phase II study of BI-505

Nov. 9, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...